SCHEMBL376992

SCHEMBL376992

CC(C)(C)OC(=O)OC(=O)[C@]1(O)CCCN1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2497821 1.00
SCHEMBL21409026 0.81
SCHEMBL2224543 0.81
SCHEMBL2434997 0.80
SCHEMBL9215170 0.80
SCHEMBL2487140 0.79
SCHEMBL5123125 0.79
SCHEMBL9637164 0.79
SCHEMBL1647597 0.79
SCHEMBL7298166 0.78

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260109715-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE PUBLIC UNIVERSITY CORPORATION YOKOHAMA CITY UNIVERSITY (JP) 2026-04-23 US disclosed
EP-4293024-B1 QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN ASTELLAS PHARMA INC (JP) 2026-04-08 EP disclosed
EP-4706774-A2 QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN Astellas Pharma Inc. (JP) 2026-03-11 EP disclosed
US-20260049072-A1 HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN ASTELLAS PHARMA INC (JP) 2026-02-19 US disclosed
US-20250340561-A1 QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN ASTELLAS PHARMA INC (JP) 2025-11-06 US disclosed
EP-4600246-A1 IMIDAZOPYRIDINE DERIVATIVES WITH BICYCLIC STRUCTURE Public University Corporation Yokohama City University (JP) 2025-08-13 EP disclosed
US-12384794-B2 Quinazoline compound for inducing degradation of G12D mutant KRAS protein ASTELLAS PHARMA INC. (JP) 2025-08-12 US disclosed
US-20250206751-A1 HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN ASTELLAS PHARMA INC. (JP) 2025-06-26 US disclosed
EP-4567033-A1 HETEROCYCLIC COMPOUND FOR INDUCING DEGRADATION OF MUTANT KRAS PROTEIN Astellas Pharma Inc. (JP) 2025-06-11 EP disclosed
US-20250064946-A1 PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND ASTELLAS PHARMA INC. (JP) 2025-02-27 US disclosed
US-5629406-A AMINO ACID DERIVATIVES SANKYO COMPANY, LIMITED (JP) 1997-05-13 US disclosed
US-5317016-A Pyrrolidylthiocarbapenem derivative SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) 1994-05-31 US disclosed
US-5202330-A Hypotensive and cardiovascular agent, reduces blood pressure in mammals E. R. SQUIBB & SONS, INC. (US) 1993-04-13 US disclosed
EP-0528678-A1 A pyrrolidylthiocarbapenem derivative SHIONOGI SEIYAKU KABUSHIKI KAISHA trading under the name of SHIONOGI &amp; CO. LTD. (JP) 1993-02-24 EP disclosed
EP-0237347-B1 1,2,3,4-Tetrahydro-6-substituted-4-aryl (or heterocyclo)-3-[(substituted amino)carbonyl]-2-thioxo (or oxo)-5-pyrimidinecarboxylic acids and esters E.R. Squibb &amp; Sons, Inc. (US) 1991-06-12 EP disclosed
EP-0237347-A2 1,2,3,4-Tetrahydro-6-substituted-4-aryl (or heterocyclo)-3-[(substituted amino)carbonyl]-2-thioxo (or oxo)-5-pyrimidinecarboxylic acids and esters E.R. Squibb &amp; Sons, Inc. (US) 1987-09-16 EP disclosed
US-4681886-A HYPOTENSIVE AGENTS E. R. SQUIBB & SONS, INC. (US) 1987-07-21 US disclosed
EP-0095584-B1 SUBSTITUTED 4-PHENOXY AND 4-PHENYLTHIO PROLINES E.R. Squibb &amp; Sons, Inc. (US) 1987-01-07 EP disclosed
EP-0204317-A2 2-Thio or oxo-4-aryl or heterocyclo-1,5(2H)-pyrimidinedicarboxylic acid diesters and 3-acyl-5-pyrimidinecarboxylic acids and esters E.R. Squibb &amp; Sons, Inc. (US) 1986-12-10 EP disclosed
EP-0095584-A2 Substituted 4-phenoxy and 4-phenylthio prolines E.R. Squibb &amp; Sons, Inc. (US) 1983-12-07 EP disclosed